

Ready for the Flood of Litigation Against Federal Agencies?

A photograph of a modern building's curved glass facade, showing multiple stories with dark window frames and light-colored panels, set against a clear sky.

2 MIN READ

January 17, 2024, 3:39 PM

By: Aaron Z. Savit, PhD, Ian Swan

Today, the Supreme Court heard oral arguments in two related cases that may have a significant impact on litigation against federal agencies – *Loper Bright Enterprises v. Raimondo* and *Relentless v. Department of Commerce*. The Court’s ruling could decide the fate of *Chevron* deference, a cornerstone of American administrative law. A series of cases in recent years have signaled that the Court is likely ready to move away from *Chevron* deference. And today, the justices’ questions indicate that the Court will almost certainly narrow *Chevron* or overturn it entirely, paving the way for an influx of challenges to decisions made by federal agencies, including FDA.

The Court’s more conservative justices seemed largely unpersuaded by the Solicitor General’s arguments for maintaining some form of *Chevron* deference. Justices Gorsuch, Kavanaugh, and Alito questioned the doctrine’s real-world workability, its impacts on legal stability and uniformity, and even its constitutionality.

The Court’s more liberal justices framed the debate as a choice between delegating interpretive authority to Agency experts, who are ultimately accountable to the public through the next presidential election, and unelected judges, who are usually appointed for life. In fact, Justice Brown Jackson went so far as expressing concern about judges becoming “uber-legislators” in the absence of *Chevron* deference. Perhaps seeking a compromise position, Justices Kagan and Sotomayor advocated for a clearer definition of “ambiguity” under

Chevron's step one, so that courts would have clearer guidance on which cases should proceed to step two of the *Chevron* analysis.

Both liberal and conservative justices grappled with what it would look like to “*Kisor-ize*” *Chevron*. That would require the Court to determine whether there is a genuine statutory ambiguity by exhausting all the standard tools of statutory interpretation before proceeding to *Chevron* step two. But, as Justice Alito noted, courts in cases not involving an agency interpretation cannot exhaust the tools of statutory interpretation and then defer to another authority; they must always find a landing spot after applying the statutory interpretation tools.

Notably, both the Court’s more liberal justices and the Solicitor General suggested placing more emphasis on whether there was truly a statutory ambiguity in *Chevron's* step one, tacitly acknowledging that the *Chevron* analysis is likely to at least be modified, if not overturned entirely. Justice Coney Barrett’s questions suggested that she is more skeptical of abandoning *Chevron* entirely compared to some of her conservative colleagues.

In today’s oral arguments, the justices’ questions indicate that many are – at a minimum – skeptical about the continued viability of *Chevron* deference. It seems that even *Chevron* proponents recognize that judges should take a more active role in interpreting statutes and limit broad deference to agency interpretations.


As the Supreme Court prepares to narrow or eliminate the *Chevron* doctrine, a decision in these cases will likely define how administrative agencies function over the coming decades. An outcome that narrows or eliminates *Chevron* deference will undoubtedly lead to an uptick in litigation challenges and greater scrutiny of administrative decisions.

The case is one of the most consequential to come before the justices in years. . . . It would very likely sharply limit the power of many federal agencies to regulate not only fisheries and the environment, but also health care, finance, telecommunications and other activities, legal experts say.

© www.nytimes.com/...



Related People



Aaron Z. Savit, PhD



Ian Swan

Related Services

Intellectual Property
Litigation & Trials

To subscribe to our publications, [click here](#).

TAGS

biosimilars, healthcare, pharma, regulatory

News & Insights

- American Bar Association 2025 Asia-Pacific Conference
SPEAKING ENGAGEMENT ANTITRUST
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference
SPONSORSHIP ANTITRUST
- GCR Live: Law Leaders Global 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Corporate Counsel Retreat 2025
SPONSORSHIP ANTITRUST
- Forecasting Health Care Antitrust Under a Second Trump Administration
PODCAST ANTITRUST
- GCR 100 2025 Ranks Axinn Antitrust Group in Top Categories
AWARDS & RECOGNITIONS ANTITRUST
- What Trump's FTC Picks Mean for Bio-Pharma Dealmaking and PBMs
MEDIA MENTIONS ANTITRUST
- Capitol Forum Health Care Competition Conference 2024
SPEAKING ENGAGEMENT ANTITRUST
- Ethical Considerations for Cybersecurity, IP Transactions and Avoiding USPTO Sanctions (EIP241212)
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Albertsons Ends Merger Deal, Accuses Kroger of 'Self-Serving Conduct'
MEDIA MENTIONS ANTITRUST

© 2024 Axinn, Veltrop & Harkrider LLP. All Rights Reserved